<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9287">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05701241</url>
  </required_header>
  <id_info>
    <org_study_id>EDGE 002337</org_study_id>
    <nct_id>NCT05701241</nct_id>
  </id_info>
  <brief_title>Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients</brief_title>
  <acronym>SAUNA</acronym>
  <official_title>Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients - The SAUNA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Belgium Health Care Knowledge Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled,&#xD;
      pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic&#xD;
      (GEP) neuroendocrine tumours (NET) with progressive disease on first-line therapy with&#xD;
      somatostatine analogues (SSA). Eligible patients will be divided into two substudies&#xD;
      according to the second-line therapy of choice (peptide receptor radionuclide therapy (PRRT)&#xD;
      or targeted therapy, at the discretion of the local investigator). Patients within each&#xD;
      substudy will be randomised 1:1 between continuation or withdrawal from SSA at the start of&#xD;
      second-line systemic therapy. Stratification will occur according to study site and according&#xD;
      to the Ki67 value (below 10% (grade 1 and low grade 2) and equal to or above 10% (high grade&#xD;
      2)).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2023</start_date>
  <completion_date type="Anticipated">April 2034</completion_date>
  <primary_completion_date type="Anticipated">April 2029</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudy</measure>
    <time_frame>18 months after start second-line treatment</time_frame>
    <description>PFS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The difference in time to deterioration (TTD) in patients continuing or stopping second-line therapy with SSAs per substudy</measure>
    <time_frame>18 months after start second-line treatment</time_frame>
    <description>TTD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival rate according to RECIST 1.1</measure>
    <time_frame>18 months after start second-line treatment</time_frame>
    <description>PFS rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in a pooled progression-free survival of both substudies</measure>
    <time_frame>18 months after start second-line treatment</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in a pooled time to deterioration of both substudies</measure>
    <time_frame>18 months after start second-line treatment</time_frame>
    <description>TTD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) per substudy and pooled over both substudies</measure>
    <time_frame>Time until death; assessed up to 5 years after treatment phase</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival pooled over both substudies</measure>
    <time_frame>Time until death; assessed up to 5 years after treatment phase</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates (RR) per substudy</measure>
    <time_frame>18 months after start second-line treatment</time_frame>
    <description>RR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates over both substudies</measure>
    <time_frame>18 months after start second-line treatment</time_frame>
    <description>RR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) measurement with questionnaire</measure>
    <time_frame>End of study (6.5 years after start second-line treatment)</time_frame>
    <description>QoL measurement with 30-item Quality of Life Questionnaire (QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) measurement with questionnaire</measure>
    <time_frame>End of study (6.5 years after start second-line treatment)</time_frame>
    <description>QoL measurement with 21-item QoL questionnaire in the gut, pancreas and liver neuroendocrine tumours (QLQ-GINET21)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) measurement with questionnaire</measure>
    <time_frame>End of study (6.5 years after start second-line treatment)</time_frame>
    <description>QoL measurement with EuroQol-5 Dimensions-5 Level questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>End of study (6.5 years after start second-line treatment)</time_frame>
    <description>Health technology assessment (HTA) analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug safety</measure>
    <time_frame>18 months after start second-line treatment</time_frame>
    <description>Safety will be reported in terms of incidence and severity of (serious) adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Gastroenteropancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>somatostatin analogs continuation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Somatostatin analog (octreotide long-acting release (LAR) 30 mg or lanreotide 120 mg) will be given every four weeks for a duration of 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>somatostatin analogs withdrawal</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Somatostatin analog treatment (octreotide LAR 30 mg or lanreotide 120 mg) will be withdrawn for a duration of 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin analog</intervention_name>
    <description>Somatostatin analog treatment every 4 weeks</description>
    <arm_group_label>somatostatin analogs continuation</arm_group_label>
    <other_name>lanreotide</other_name>
    <other_name>octreotide</other_name>
    <other_name>sandostatin</other_name>
    <other_name>somatuline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Written informed consent prior to any study-related procedures&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2,&#xD;
&#xD;
          -  Histologically-proven diagnosis of locally advanced or metastatic, non-functional,&#xD;
             well-differentiated World Health Organisation 2019 grade 1-2 GEP NET&#xD;
&#xD;
          -  Documented radiological disease progression on first-line SSA treatment&#xD;
&#xD;
          -  For targeted therapy substudy: indication to start with either sunitinib or everolimus&#xD;
             as second-line therapy, according to local investigator&#xD;
&#xD;
          -  For PRRT substudy: indication to start with PRRT with Lutetium (177Lu) oxodotreotide&#xD;
             as second-line therapy, according to local investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indication for chemotherapy treatment of GEP NET in second-line&#xD;
&#xD;
          -  Presence of poorly differentiated grade 3 neuroendocrine carcinoma (NEC),&#xD;
             well-differentiated grade 3 NET or rapidly progressive NET&#xD;
&#xD;
          -  Prior treatment with everolimus, sunitinib or PRRT&#xD;
&#xD;
          -  Contra-indication, proven allergy or other indication than functional NET for the use&#xD;
             of a SSA&#xD;
&#xD;
          -  Patient showing progressive disease while being on a lower than the registered dose&#xD;
&#xD;
          -  Functional NET, defined as the presence of clinical and biochemical evidence of a&#xD;
             hormonal NET-related syndrome&#xD;
&#xD;
          -  Patient undergoing palliative, systemic oncological treatment for other malignancy&#xD;
             than GEP NET&#xD;
&#xD;
          -  Concurrent anti-cancer treatment in another investigational trial&#xD;
&#xD;
          -  Any abnormal findings at baseline, clinical finding, including psychiatric and&#xD;
             behavioural problems, or any other medical condition(s) or laboratory findings that,&#xD;
             in the opinion of the investigator, might jeopardize the patient's safety or decrease&#xD;
             the chance of obtaining satisfactory data needed to achieve the objective(s) of the&#xD;
             study&#xD;
&#xD;
          -  Pregnant or lactating patient at screening or if the patient wishes to get pregnant&#xD;
             during treatment phase of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Peeters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc U Peeters, MD</last_name>
    <phone>03821</phone>
    <phone_ext>4366</phone_ext>
    <email>sauna@uza.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Timon Vandamme, MD</last_name>
    <email>timon.vandamme@uza.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Wim Demey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Rivierenland</name>
      <address>
        <city>Rumst</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marijke Ulenaers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <state>East Flanders</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITAZ</name>
      <address>
        <city>Sint-Niklaas</city>
        <state>East-Flanders</state>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Willem Lybaert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Chris Verslype</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Monica</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Luc Poelmans</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GZA</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U.B.</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Ioannis Karfis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Ivan Borbath</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Peeters</last_name>
      <email>sauna@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sart Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurence Lousberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Voorkempen</name>
      <address>
        <city>Malle</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Wim Demey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijstate</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Theo Van Voorthuizen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Loes Latten-Jansen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <state>North Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Wouter Dercksen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Heinz-Josef Klumpen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Annemiek Walenkamp</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Wouter de Herder</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 5, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>January 31, 2023</last_update_submitted>
  <last_update_submitted_qc>January 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>somatostatin analogues</keyword>
  <keyword>neuroendocrine tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

